top
Search terms
Results 1 - 7 of 7 - ordered by :
Ehjournal

[...]despite the need for effective mechanical circulatory support in CSMI, current devices, as tested, have not been demonstrated to improve short- or long-term survival rates. Introduction ...

European Heart Journal, Werdan, Karl, Gielen, Stephan, Ebelt, Henning, Hochman, Judith S.

Date : 14/01/2014 Item size : 496296 bytes
Ehjournal

[...]despite the need for effective mechanical circulatory support in CSMI, current devices, as tested, have not been demonstrated to improve short- or long-term survival rates. Introduction ...

European Heart Journal, Werdan, Karl, Gielen, Stephan, Ebelt, Henning, Hochman, Judith S.

Date : 14/01/2014 Item size : 501976 bytes
Ehjournal

Conclusion CS on admission patients have a worse outcome but benefit equally from emergency revascularization as delayed CS patients, emphasizing the need for rapid and direct access of CS on ...

European Heart Journal, Jeger, Raban V., Harkness, Shannon M., Ramanathan, Krishnan, Buller, Christopher E., Pfisterer, Matthias E., Sleeper, Lynn A., Hochman, Judith S.

Date : 01/03/2006
Ehjournal

Conclusion CS on admission patients have a worse outcome but benefit equally from emergency revascularization as delayed CS patients, emphasizing the need for rapid and direct access of CS on ...

European Heart Journal, Jeger, Raban V., Harkness, Shannon M., Ramanathan, Krishnan, Buller, Christopher E., Pfisterer, Matthias E., Sleeper, Lynn A., Hochman, Judith S.

Date : 01/03/2006 Item size : 179682 bytes
Ehjournal

Abstract Aims Pexelizumab, a monoclonal antibody inhibiting C5, reduced 90 day mortality and shock in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial without ...

European Heart Journal, Théroux, Pierre, Armstrong, Paul W., Mahaffey, Kenneth W., Hochman, Judith S., Malloy, Kevin J., Rollins, Scott, Nicolau, Jose C., Lavoie, Joel, Luong, The Minh, Burchenal, ...

Date : 01/10/2005
Ehjournal

Abstract Aims Pexelizumab, a monoclonal antibody inhibiting C5, reduced 90 day mortality and shock in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial without ...

European Heart Journal, Théroux, Pierre, Armstrong, Paul W., Mahaffey, Kenneth W., Hochman, Judith S., Malloy, Kevin J., Rollins, Scott, Nicolau, Jose C., Lavoie, Joel, Luong, The Minh, Burchenal, ...

Date : 01/10/2005 Item size : 173396 bytes
Ehjournal

Abstract Aims Pexelizumab, a monoclonal antibody inhibiting C5, reduced 90 day mortality and shock in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial without ...

European Heart Journal, Théroux, Pierre, Armstrong, Paul W., Mahaffey, Kenneth W., Hochman, Judith S., Malloy, Kevin J., Rollins, Scott, Nicolau, Jose C., Lavoie, Joel, Luong, The Minh, Burchenal, ...

Date : 01/10/2005